Skin Cancer Rates Five Times Higher Than in 70s

“The rates of people diagnosed with malignant melanoma, the most serious form of skin cancer, are now five times higher than 40 years ago, according to figures announced by Cancer Research UK.

“More than 13,000 people are now developing the disease every year compared with around 1,800 in 1975.

“The latest incidence rates show around 17 people in every 100,000 are diagnosed with malignant melanoma in Great Britain every year. This is compared to just over 3 per 100,000 in the mid 70s.”


Dysfunctional Oxidative Phosphorylation Makes Malignant Melanoma Cells Addicted to Glycolysis Driven by the V600EBRAF Oncogene

Oncogene addiction describes how cancer cells exhibit dependence on single oncogenes to escape apoptosis and senescence. While oncogene addiction constitutes the basis for new cancer treatment strategies targeting individual kinases and pathways activated by oncogenic mutations, the biochemical basis for this addiction is largely unknown. Here we provide evidence for a metabolic rationale behind the addiction to V600EBRAF in two malignant melanoma cell lines…”


Vemurafenib and radiation therapy in melanoma brain metastases

“Brain metastases in malignant melanoma carries a poor prognosis with minimal response to any therapy. The purpose of this pilot analysis was to find the effectiveness of vemurafenib, an oral BRAF inhibitor, and radiation therapy in V600 mutated melanoma with brain metastases. BRAF mutation status of the melanoma patients was determined by real-time PCR assay…”


HIF1α and HIF2α independently activate SRC to promote melanoma metastases

Malignant melanoma is characterized by a propensity for early lymphatic and hematogenous spread. The hypoxia-inducible factor (HIF) family of transcription factors is upregulated in melanoma by key oncogenic drivers. HIFs promote the activation of genes involved in cancer initiation, progression, and metastases. Hypoxia has been shown to enhance the invasiveness and metastatic potential of tumor cells by regulating the genes involved in the breakdown of the ECM as well as genes that control motility and adhesion of tumor cells…”